Legal & General Group
THRX

Legal & General Group’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Legal & General Group’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,930
Closed -$7.82K – 3395
2023
Q4 		$7.82K Hold
1,930
– – ﹤0.01% 3270
2023
Q3 		$5.19K Hold
1,930
– – ﹤0.01% 3361
2023
Q2 		$18K Buy
1,930
+497
+35% +$4.9K ﹤0.01% 3153
2023
Q1 		$12.7K Hold
1,433
– – ﹤0.01% 3163
2022
Q4 		$7.14K Hold
1,433
– – ﹤0.01% 3314
2022
Q3 		$8K Sell
1,433
-529
-27% -$3.74K ﹤0.01% 3370
2022
Q2 		$11K Buy
1,962
+903
+85% +$7.46K ﹤0.01% 3370
2022
Q1 		$12K Hold
1,059
– – ﹤0.01% 3373
2021
Q4 		$13K Buy
+1,059
New +$16K ﹤0.01% 3418

Legal & General Group's THRX Position: Q1 2024 in Review

Legal & General Group sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 1,930 shares — an estimated $7.82K sold.

Legal & General Group first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $18K in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Legal & General Group reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Legal & General Group sold 1,930 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $7.82K.
  • Legal & General Group first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Legal & General Group's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $18K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Legal & General Group's 13F filing for Q1 2024, filed 14 May 2024.